Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Pfizer Inc. : Pfizer Names Olivier Brandicourt as President and General Manager, Emerging Markets and Established Products Business Units

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/23/2012 | 01:35pm CEST

John Young Named President and General Manager, Primary Care Business Unit

Pfizer Inc. (NYSE: PFE) named Olivier Brandicourt as President and General Manager of the Emerging Markets and Established Products Business Units, effective June 1, 2012. He will succeed David Simmons, who is leaving Pfizer to become the Chairman and CEO of Pharmaceutical Product Development Inc. (PPD), a privately held global contract research organization.

"Olivier is ideally suited to take on this new role," said Ian Read, Pfizer Chairman and CEO. "He has more than 20 years of global experience in the pharmaceutical industry. Olivier is both a physician and proven business leader who understands the many challenges of today's changing industry and healthcare landscape."

Dr. Brandicourt has held senior positions at Pfizer across a range of disciplines, including medical and marketing, as well as country and regional management roles in Latin America, Europe, Canada, the United Kingdom and the United States. Most recently, he served as President and General Manager of the Primary Care Business Unit and is a member of the Pfizer Executive Leadership Team. He is an Honorary Fellow of the Royal College of Physicians in London and a trustee of the Children's Aid Society of New York.

John Young, currently Regional President of Europe and Canada for the Primary Care business, is appointed President and General Manager of the Primary Care Business Unit and will join the Company's Executive Leadership Team, effective June 1, 2012. Over his 25-year career with Pfizer, Mr. Young has held a number of commercial positions with the company, including country and regional management roles in Australia/New Zealand and the United Kingdom.

"John has a deep understanding of the primary care landscape and will be a strong leader for this significant part of our business. We are indeed fortunate to have such a deep bench of talented leaders who can quickly assume new roles and maintain our momentum," Read added.

"We thank David for his contributions throughout his 15-year career at Pfizer. Under his leadership, the Established Products Business Unit was created, expanding Pfizer's market reach while also helping to ensure patients have the access to high-quality, affordable medicines they need."

Pfizer Inc: Working Together for a Healthier World™

At Pfizer (NYSE: PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Pfizer Inc.
Media Contact:
Joan Campion, 212-733-2798
or
Investors Contact:
Chuck Triano, 212-733-3901


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
03/25 Merck KGaA and Pfizer break into cancer immunotherapy
03/25 Pfizer, Merck KGaA score watershed FDA nod on cancer immunotherapy Bavencio
03/24 GLOBAL GLAUCOMA THERAPEUTICS MARKET : Allergan, Merck, Novartis, Pfizer, Santen..
03/24 PFIZER : Receives Positive CHMP Opinion for TRUMENBA® for Prevention of Meningoc..
03/24 PFIZER : Doctors Without Borders Urges Pharmaceutical Corporations to Release Cl..
03/24 PFIZER : Receives Positive CHMP Opinion for Trumenba for Prevention of Meningoco..
03/24 PFIZER : FDA Grants Approval for BAVENCIO® (avelumab)
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23 TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Advertisement
Financials ($)
Sales 2017 53 525 M
EBIT 2017 20 455 M
Net income 2017 13 219 M
Debt 2017 25 072 M
Yield 2017 3,76%
P/E ratio 2017 13,99
P/E ratio 2018 13,28
EV / Sales 2017 4,25x
EV / Sales 2018 3,98x
Capitalization 202 474 M
More Financials
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 38,1 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Ole Isacson Chief Scientific Officer
W. Don Cornwell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%202 474
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.60%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results